Get Thin MD Review

Best for: lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also available

Get Thin MD is a US-based async telehealth platform operated by Get Thin MD LLC, offering compounded semaglutide and tirzepatide injections plus brand-name Ozempic and Zepbound where medically appropriate. Nationwide availability, no insurance or office visits required, with doctor-led personalized plans starting at $169/month on the 3-month compounded semaglutide plan. Alongside GLP-1s the platform also offers sermorelin (muscle growth), NAD+, HRT, and hair-loss treatments — GLP-1 is one vertical within a broader wellness funnel.

Medium confidence · Last verified 2026-04-09 via Chrome MCP live pull · How we verify provider data

7.9
★★★★☆4
CompoundedSemaglutideTirzepatideBrandOzempicZepboundAll 50 States
$169/mo
Visit Get Thin MD

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

The Bottom Line

Get Thin MD is one of the most affordable GLP-1 options on the market.

Score: 7.9/10Best for: lowest-priced compounded semaglutide on a 3-month commitment, with brand-name Ozempic/Zepbound also availableFrom: $169/mo

Score Breakdown

Value
8.5
Effectiveness
7.5
User Experience
7.5
Trust & Safety
7.5
Accessibility
8.5
Support
7.5

Pricing

DoseFormPrice/mo
Compounded Semaglutide (3-Month Plan)compounded$169
Compounded Semaglutide (Monthly Plan)compounded$199
Compounded Tirzepatide (Monthly Plan)compounded$299

✓ Pros

  • •3-month compounded semaglutide plan at $169/month is one of the lowest ongoing prices in the compounded GLP-1 category
  • •Price-lock positioning: 'Same price, every dose. No hidden fees.' — per the product page
  • •Both compounded and brand-name options available in one platform (compounded semaglutide, compounded tirzepatide, plus brand-name Ozempic and Zepbound where medically appropriate)
  • •Nationwide availability with async evaluation — no in-person visit required
  • •Broader wellness platform that also offers sermorelin, NAD+, HRT, and hair-loss treatments, so patients can consolidate multiple protocols with one provider
  • •Proper FDA compounding disclaimer on the product page: "The FDA does not review or approve any compounded medications for safety or effectiveness."

✗ Cons

  • •Compounded medications are not FDA-approved as finished products and lack the formal safety/efficacy review of brand-name Ozempic, Wegovy, Zepbound, and Mounjaro
  • •Pharmacy partners not publicly named on the site — no independent way to verify 503A/503B compounding source or per-batch testing
  • •State-by-state availability claimed as nationwide but no verbatim state list is published — needs intake signup to confirm whether every state is actually served
  • •Clinical efficacy headline ("9.6 pounds in 30 days") is based on 645 self-reported patient data points from Jan 2024 – Apr 2025 — self-reported data is lower-quality than a randomized trial
  • •Broader wellness funnel (sermorelin + NAD+ + HRT alongside GLP-1s) means some patients may be upsold into off-weight-loss protocols — readers looking specifically for GLP-1 care should know the platform has a wider vertical mix

Ready to start with Get Thin MD?

Starting at $169/month. See current pricing and start your free consultation.

Visit Get Thin MD →

Sources & methodology

Our Get Thin MD review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.

Sources & methodology — as of April 2026
  1. 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
  5. 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  8. 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  9. 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  10. 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  11. 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  12. 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.

Alternatives to Get Thin MD

7.1/ 10

AgelessRx

Best for: longevity-focused GLP-1 care (pending verification)

★★★★☆3.6

Editorial score · methodology

$199/mo
CompoundedSemaglutide
Get StartedRead full AgelessRx review →
7.7/ 10

Alan Meds

Best for: budget-conscious shoppers

★★★★☆3.9

Editorial score · methodology

$99/mo
CompoundedSemaglutideTirzepatide
Get StartedRead full Alan Meds review →
7.1/ 10

Alloy

Best for: women in menopause with comprehensive GLP-1 formulary needs (pending verification)

★★★★☆3.6

Editorial score · methodology

$199/mo
CompoundedSemaglutide
Get StartedRead full Alloy review →
See all alternatives to Get Thin MD →

Frequently Asked Questions

Ready to start with Get Thin MD?

Starting at $169/month. See current pricing and start your free consultation.

Visit Get Thin MD →